Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2116810 | Cancer Letters | 2007 | 8 Pages |
Abstract
YM529, a new third generation bisphosphonate, induced apoptosis of a human breast cancer cell line, MX-1. Cytotoxic activity of YM529 was more potent than that of incadronate. YM529 activated caspase-9, but not caspase-8, and induced the release of cytochrome c into cytosol. YM529 increased Bax expression and decreased Bcl-2 expression, while it did not induce caspase-8-dependent Bid truncation. Farnesyl pyrophosphate prevented YM529-mediated cytotoxicity. These results suggest that YM529 is a potent therapeutic agent for human breast cancers, activating the mitochondria-dependent apoptotic pathway through the inhibition of protein farnesylation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hiroo Nakajima, Junji Magae, Mie Tsuruga, Koichi Sakaguchi, Ikuya Fujiwara, Mitsuhiko Mizuta, Kiyoshi Sawai, Hisakazu Yamagishi, Naruhiko Mizuta,